Literature DB >> 24096545

QM-FISH analysis of the genes involved in the G1/S checkpoint signaling pathway in triple-negative breast cancer.

Sheng Zhang1, Yingbo Shao, Guofang Hou, Jingchao Bai, Weiping Yuan, Linping Hu, Tao Cheng, Anders Zetterberg, Jin Zhang.   

Abstract

This study was conducted to analyze copy number alterations (CNAs) of the genes involved in the G1/S checkpoint signaling pathway of triple-negative breast cancer (TNBC) and to evaluate their clinical value in the prognosis of TNBC. Quantitative multi-gene fluorescence in situ hybridization was used to study CNAs of the genes involved in the G1/S checkpoint signaling pathway, including cyclin d1 (CCND1), c-Myc, p21, cell-cycle-checkpoint kinase 2 gene, p16, retinoblastoma (Rb1), murine double minute 2 (Mdm2) and p53, in 60 TNBC samples and 60 non-TNBC samples. In comparison with the non-TNBC samples, CNAs of the genes involved in the G1/S checkpoint signaling pathway were more frequently observed in the TNBC samples (p = 0.000). Out of a total of eight genes, six (CCND1, c-Myc, p16, Rb1, Mdm2, and p53) exhibited significantly different CNAs between the TNBC group and the non-TNBC group. Univariate survival analysis revealed that the gene amplification of c-Myc (p = 0.008), Mdm2 (p = 0.020) and the gene deletion of p21 (p = 0.004), p16 (p = 0.015), and Rb1 (p = 0.028) were the independent predictive factor of 5-year OS for patients with TNBC. Cox multivariate analysis revealed that the gene amplification of c-Myc (p = 0.026) and the gene deletion of p21 (p = 0.019) and p16 (p = 0.034) were independent prognostic factors affecting the 5-year OS for TNBC. CNAs of the genes involved in the G1/S checkpoint signaling pathway presented a higher rate of incidence in TNBC than in non-TNBC, which could indicate one of the molecular mechanisms for the specific biological characteristics of TNBC. The genes c-Myc, p21, and p16 were correlated with the prognosis of TNBC and therefore may have potential clinical application values in the prognostic prediction of TNBC.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24096545     DOI: 10.1007/s13277-013-1246-5

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  29 in total

1.  Bmi-1, c-myc, and Snail expression in primary breast cancers and their metastases--elevated Bmi-1 expression in late breast cancer relapses.

Authors:  Kristiina Joensuu; Jaana Hagström; Marjut Leidenius; Caj Haglund; Leif C Andersson; Hannu Sariola; Päivi Heikkilä
Journal:  Virchows Arch       Date:  2011-06-03       Impact factor: 4.064

Review 2.  Regulation of the cell cycle by the Rb tumor suppressor family.

Authors:  M E Ewen
Journal:  Results Probl Cell Differ       Date:  1998

3.  Interactions between p53 and MDM2 in a mammalian cell cycle checkpoint pathway.

Authors:  C Y Chen; J D Oliner; Q Zhan; A J Fornace; B Vogelstein; M B Kastan
Journal:  Proc Natl Acad Sci U S A       Date:  1994-03-29       Impact factor: 11.205

4.  Therapeutically activating RB: reestablishing cell cycle control in endocrine therapy-resistant breast cancer.

Authors:  Chellappagounder Thangavel; Jeffry L Dean; Adam Ertel; Karen E Knudsen; C Marcelo Aldaz; Agnieszka K Witkiewicz; Robert Clarke; Erik S Knudsen
Journal:  Endocr Relat Cancer       Date:  2011-04-28       Impact factor: 5.678

5.  INK4a gene expression and methylation in primary breast cancer: overexpression of p16INK4a messenger RNA is a marker of poor prognosis.

Authors:  R Hui; R D Macmillan; F S Kenny; E A Musgrove; R W Blamey; R I Nicholson; J F Robertson; R L Sutherland
Journal:  Clin Cancer Res       Date:  2000-07       Impact factor: 12.531

Review 6.  A review of triple-negative breast cancer.

Authors:  Roohi Ismail-Khan; Marilyn M Bui
Journal:  Cancer Control       Date:  2010-07       Impact factor: 3.302

7.  Breast cancer manifested by hematologic disorders.

Authors:  Takashi Ishikawa; Daisuke Shimizu; Ayako Kito; Ikuko Ota; Takeshi Sasaki; Mikiko Tanabe; Akimitsu Yamada; Hitoshi Arioka; Satoru Shimizu; Junichi Wakasugi; Ryutaro Mori; Takashi Chishima; Yasushi Ichikawa; Itaru Endo
Journal:  J Thorac Dis       Date:  2012-12       Impact factor: 2.895

8.  The E2F-family proteins induce distinct cell cycle regulatory factors in p16-arrested, U343 astrocytoma cells.

Authors:  P B Dirks; J T Rutka; S L Hubbard; S Mondal; P A Hamel
Journal:  Oncogene       Date:  1998-08-20       Impact factor: 9.867

9.  EGFR, HER-2/neu, cyclin D1, p21 and p53 in correlation to cell proliferation and steroid hormone receptor status in ductal carcinoma in situ of the breast.

Authors:  Annette Lebeau; Angela Unholzer; Gudrun Amann; Michaela Kronawitter; Ingo Bauerfeind; Andrea Sendelhofert; Anette Iff; Udo Löhrs
Journal:  Breast Cancer Res Treat       Date:  2003-05       Impact factor: 4.872

10.  Molecular profiling including epidermal growth factor receptor and p21 expression in high-risk breast cancer patients as indicators of outcome.

Authors:  G Somlo; P Chu; P Frankel; W Ye; S Groshen; J H Doroshow; K Danenberg; P Danenberg
Journal:  Ann Oncol       Date:  2008-07-17       Impact factor: 32.976

View more
  9 in total

1.  Lidocaine enhances the efficacy of palbociclib in triple-negative breast cancer.

Authors:  Beom Seok Han; Kyung Hee Jung; Ji Eun Lee; Young-Chan Yoon; Soyeon Ko; Min Seok Park; Yun Ji Lee; Sang Eun Kim; Ye Jin Cho; Pureunchowon Lee; Joo Han Lim; Eunsoo Jang; Hyunzu Kim; Soon-Sun Hong
Journal:  Am J Cancer Res       Date:  2022-07-15       Impact factor: 5.942

2.  Fbxo22 inhibits metastasis in triple-negative breast cancer through ubiquitin modification of KDM5A and regulation of H3K4me3 demethylation.

Authors:  Siqiaozhi Li; Jinsong He; Xin Liao; Yixuan He; Rui Chen; Junhui Chen; Sean Hu; Jia Sun
Journal:  Cell Biol Toxicol       Date:  2022-09-16       Impact factor: 6.819

3.  Contribution of personalized Cyclin D1 genotype to triple negative breast cancer risk.

Authors:  Liang-Chih Liu; Chen-Hsien Su; Hwei-Chung Wang; Wen-Shin Chang; Chia-Wen Tsai; Ming-Chei Maa; Chang-Hai Tsai; Fuu-Jen Tsai; Da-Tian Bau
Journal:  Biomedicine (Taipei)       Date:  2014-08-27

4.  BCL-XL blockage in TNBC models confers vulnerability to inhibition of specific cell cycle regulators.

Authors:  Olivier Castellanet; Fahmida Ahmad; Yaron Vinik; Gordon B Mills; Bianca Habermann; Jean-Paul Borg; Sima Lev; Fabienne Lamballe; Flavio Maina
Journal:  Theranostics       Date:  2021-09-03       Impact factor: 11.556

5.  Clonal phylogeny and evolution of critical cytogenetic aberrations in multiple myeloma at single-cell level by QM-FISH.

Authors:  Yuting Yan; Xiaoqi Qin; Jiahui Liu; Huishou Fan; Wenqiang Yan; Lanting Liu; Chenxing Du; Zhen Yu; Yan Xu; Mu Hao; Shuhui Deng; Weiwei Sui; Rui Lyu; Wei Liu; Qi Wang; Dehui Zou; Linping Hu; Jianxiang Wang; Yu-Tzu Tai; Kenneth C Anderson; Lei Zhang; Tao Cheng; Anders Zetterberg; Nikhil C Munshi; Lugui Qiu; Gang An
Journal:  Blood Adv       Date:  2022-01-25

6.  Fluorescence in situ hybridization (FISH): an increasingly demanded tool for biomarker research and personalized medicine.

Authors:  Linping Hu; Kun Ru; Li Zhang; Yuting Huang; Xiaofan Zhu; Hanzhi Liu; Anders Zetterberg; Tao Cheng; Weimin Miao
Journal:  Biomark Res       Date:  2014-02-05

7.  Zn-driven discovery of a hydrothermal vent fungal metabolite clavatustide C, and an experimental study of the anti-cancer mechanism of clavatustide B.

Authors:  Panpan Ye; Ling Shen; Wei Jiang; Ying Ye; Chen-Tung Arthur Chen; Xiaodan Wu; Kuiwu Wang; Bin Wu
Journal:  Mar Drugs       Date:  2014-05-28       Impact factor: 5.118

8.  A molecular pathology method for sequential fluorescence in situ hybridization for multi-gene analysis at the single-cell level.

Authors:  Linping Hu; Xiuxiu Yin; Jiangman Sun; Anders Zetterberg; Weimin Miao; Tao Cheng
Journal:  Oncotarget       Date:  2016-06-23

9.  The anti-tumor efficacy of CDK4/6 inhibition is enhanced by the combination with PI3K/AKT/mTOR inhibitors through impairment of glucose metabolism in TNBC cells.

Authors:  Daniele Cretella; Andrea Ravelli; Claudia Fumarola; Silvia La Monica; Graziana Digiacomo; Andrea Cavazzoni; Roberta Alfieri; Alessandra Biondi; Daniele Generali; Mara Bonelli; Pier Giorgio Petronini
Journal:  J Exp Clin Cancer Res       Date:  2018-03-27
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.